Tempus AI said on Monday it would acquire Personalis for about $1.5 billion to bringing its cancer test to the AI-enabled precision medicine firm’s oncology portfolio.
July 20, 2026 - 15:09
By Pharos Investment Advisors Comments are Off
Tempus AI said on Monday it would acquire Personalis for about $1.5 billion to bringing its cancer test to the AI-enabled precision medicine firm’s oncology portfolio.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014

Copyright 2023©. All Rights Reserved